Orion OYJ Unsponsored ADR (OTCMKTS:ORINY – Get Free Report) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 2,886 shares, an increase of 5,345.3% from the October 15th total of 53 shares. Based on an average daily trading volume, of 1,238 shares, the days-to-cover ratio is presently 2.3 days. Currently, 0.0% of the company’s stock are short sold.
Analysts Set New Price Targets
Separately, Jefferies Financial Group raised shares of Orion OYJ from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 26th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Orion OYJ currently has a consensus rating of “Buy”.
Get Our Latest Stock Analysis on ORINY
Orion OYJ Stock Performance
Shares of OTCMKTS ORINY opened at $56.92 on Wednesday. Orion OYJ has a 52 week low of $33.62 and a 52 week high of $58.15. The firm has a market cap of $16.07 billion, a price-to-earnings ratio of 21.00 and a beta of 0.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.64. The business’s 50-day simple moving average is $49.70 and its 200-day simple moving average is $42.36.
Orion OYJ (OTCMKTS:ORINY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $0.68 earnings per share for the quarter. The business had revenue of $623.96 million during the quarter. Orion OYJ had a net margin of 30.25% and a return on equity of 54.09%.
Orion OYJ Company Profile
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures and markets medicines for human and veterinary use. Its portfolio includes prescription and over-the-counter medicines, as well as active pharmaceutical ingredients supplied to other pharmaceutical companies. Founded in 1917 and headquartered in Espoo, Finland, Orion has a long history in the pharmaceutical industry. The company focuses on areas including oncology, neurology and respiratory diseases, and develops some products in collaboration with international pharmaceutical partners.
See Also
- Five stocks we like better than Orion OYJ
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
- The Trade Desk Beats on Revenue, But the Fine Print Matters
Receive News & Ratings for Orion OYJ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion OYJ and related companies with MarketBeat.com's FREE daily email newsletter.
